Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 248

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Bone Turnover Matters: The Raloxifene Treatment Paradox of Dramatic Decreases in Vertebral Fractures Without Commensurate Increases in Bone Density

Open access
Riggs, B. Lawrence, Melton, L. Joseph · 2002 · Journal of Bone and Mineral Research

Abstract

The summum bonum of osteoporosis treatment is the prevention of new fractures. In vitro studies have shown that 60-80% of the compressive strength of bone is caused by its mineral content.1 Correspondingly, observational studies show that baseline bone mineral density (BMD) measurements at multiple skeletal sites can predict various types of osteoporotic fractures in postmenopausal women.2 In general, a decrease in BMD of 1.0 SD increases the risk of future fractures by ∼2.0-fold. The observational data from epidemiological studies have been confirmed by results of randomized clinical trials (RCTs) showing that antiresorptive agents both increase BMD and decrease vertebral fractures.3 These considerations have led to the widespread belief that changes in BMD can serve as a surrogate for assessing treatment effects on fracture risk. Based mainly on the failure of large increases in BMD induced by sodium fluoride therapy to reduce fracture risk,4 the U.S. Food and Drug Administration has not allowed surrogate markers for fractures such as BMD to be used as primary endpoints for assessing efficacy of antiosteoporosis drugs. However, sodium fluoride therapy alters bone crystalline structure and reduces bone strength,5 so these results cannot be generalized to other treatments. Raloxifene is a selective estrogen receptor modulator (SERM) with a spectrum of tissue-specific agonist-antagonist effects on estrogen target tissues but that acts on bone as an estrogen agonist.6 In the large MORE trial of 7705 women with osteoporosis,7 3 years of raloxifene treatment in dosages of 30 mg/day or 60 mg/day increased BMD at the lumbar spine by 2.6% and 2.7%, respectively, and at the femoral neck by 2.1% and 2.4%, respectively, as compared with placebo. These modest increases in BMD were associated with large decreases in vertebral fractures of 38% and 41% for the two dosages, respectively. Similarly, in the PROOF trial, treatment with nasal spray calcitonin increased lumbar spine BMD by only 1.2% but decreased vertebral fracture risk by 36%.8 However, neither raloxifene7 nor nasal spray calcitonin8 treatment reduced the risk for hip and other nonvertebral fractures. By contrast, the more potent antiresorptive agents estrogen,9 alendronate,10 and risedronate11 increased lumbar spine BMD over 1-3 years by 5.3-8.8%, but RCTs with these agents have resulted in reductions in the vertebral fracture rate of about 40-50% (reviewed by Faulkner12), only slightly more than were achieved with raloxifene or calcitonin therapy. In this issue of the Journal, Sarkar et al.13 report on an extensive statistical reanalysis of the MORE data to assess further the relationship between changes in BMD and changes in vertebral fracture risk. Using logistic regression models with the two dosages of raloxifene pooled, they find that fracture risk varied inversely with baseline BMD values but that the decrease in vertebral fracture risk was similar across the range of increases in femoral neck or lumbar spine BMD and that only a small fraction of the observed reduction in vertebral fracture risk with raloxifene therapy could be accounted for by the increase in lumbar spine BMD. The authors conclude that antiresorptive agents that induce greater increases in BMD cannot necessarily be assumed more efficacious in reducing fracture risk than those that elicit lesser increases. However, the article leaves unresolved the reason for discrepancy between the small increases in BMD and the relatively large decreases in vertebral fracture risk with raloxifene therapy. Thus, there are two paradoxes that require explanation. First, how can the modest increase in BMD induced by raloxifene or nasal spray calcitonin therapy decrease fracture risk by almost the same extent as more potent antiresorptive agents that increase BMD by a 2- to 3-fold greater extent? Second, this paradox is subsumed into an even larger paradox: Why do the small increases in BMD observed after antiresorptive therapy result in a much larger decrease in vertebral fracture rate than predicted from the relationship between BMD and vertebral fracture risk found in observational studies? We will examine the second paradox first. In 1996,14 we advanced the hypothesis that antiresorptive agents were able to reduce vertebral fracture rates substantially without inducing large increases in BMD because of their ability to normalize high bone turnover in patients with osteoporosis. We further suggested that high bone turnover contributes substantially to vertebral fracture risk because of its disruptive effect on the microarchitecture of cancellous bone. Using histomorphometry, Parfitt et al.15 have shown that increased osteoclastic activity associated with high bone turnover in postmenopausal women leads to perforative resorption of cancellous plates, loss of trabeculae, and trabecular discontinuity. Because much of the strength of cancellous bone is caused by its microarchitecture, the loss of trabecul

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1359/jbmr.2002.17.1.11

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 248

Metadata

Authors
Riggs, B. L., & Melton, L. J.
Venue
Journal of Bone and Mineral Research
Published
2002-01-01
Volume
17
Issue
1
Pages
11-14
ISSN
  • 0884-0431 (ISSN-L)
  • 1523-4681
OpenAlex
W2085072070
Cited by
248
References
6
FWCI
22.66
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bone Turnover Matters: The Raloxifene Treatment Paradox of Dramatic Decreases in Vertebral Fractures Without Commensurate Increases in Bone Density. https://app.cochat.ai/papers/10.1359/jbmr.2002.17.1.11
The paper
Riggs, B. L., & Melton, L. J. (2002). Bone Turnover Matters: The Raloxifene Treatment Paradox of Dramatic Decreases in Vertebral Fractures Without Commensurate Increases in Bone Density. Journal of Bone and Mineral Research. https://doi.org/10.1359/jbmr.2002.17.1.11

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.